ByTrending Posts
China focus: Is AstraZeneca’s $5.3B AI-Powered Alliance with…
Key Takeaways: AI as the Catalyst: CSPC’s Dual-Engine Platform Front and CenterAt the core of this partnership lies…
Can Ellipsis Health’s $45M Series A and Launch…
Key Insights: Sage Redefines AI Care Management with Empathy at the CoreEllipsis Health is introducing Sage, an emotionally…
How Tempus AI and Northwestern Use AI to…
Key Takeaways Transforming Alzheimer’s Research with AI and Precision GenomicsIn a multi-year collaboration announced today, Tempus AI (NASDAQ:…
Can Parallel Bio’s $21M Bet on Immune Organoids…
Key Highlights Organoid-AI Platform Aims to Transform Preclinical Drug DiscoveryParallel Bio’s proprietary platform replicates the human immune system…
Can BullFrog AI and Sygnature Discovery’s $30M Alliance…
Key Highlights BullFrog AI Secures Global CRO Partner to Scale AI PlatformBullFrog AI has entered a commercial collaboration…
Can Receptor.AI’s Integration of REAXENSE™ Platform Redefine Full-Stack…
Key Insights: Advanced Chemistry at ScaleReceptor.AI has incorporated the REAXENSE™ platform, developed by Canada-based Reaxense Inc., into its…
How Are NUS and UC San Diego Using…
Key Highlights: AI-Powered Personalization: Unlocking Sex-Specific Drug EfficacyThe collaboration between the National University of Singapore’s WisDM and UC…
Will XtalPi’s AI-Driven Acquisition of LCC Redraw the…
Key Highlights: AI Meets Chiral Chemistry in Strategic UK AcquisitionXtalPi Holdings Ltd. (HKEX: 2228), the AI-powered drug discovery…
Is DeepCure’s AI-Designed Oral STAT6 Inhibitor the Next…
Key Highlights: Oral Option for Dupilumab-Class PatientsDeepCure’s newly nominated candidate DC-15442 offers a breakthrough alternative to injectable biologics…
Trending Posts
Latest Stories
Is Recursion Pharmaceuticals Setting the Standard for AI-Powered Drug Discovery with Strategic Deals and a $20B+ Partnership Pipeline?
Executive Summary Recursion Pharmaceuticals has emerged as a leading clinical-stage TechBio company applying artificial intelligence,…
Can ReviR’s AI-Powered RNA Modulation Platform Convert $50M+ in Funding into Scalable Genetic Medicines?
Executive Summary ReviR Therapeutics continues to establish itself as a leader in RNA-targeting small molecule…
Can Ainnocence’s Causal AI Platform Redefine Drug Discovery Value as Pharma Expands AI Partnerships?
Strategic Overview Ainnocence is carving out a differentiated role in AI-driven drug discovery by emphasizing…
Can Standigm’s Knowledge-Graph AI Outperform AI Peers Like Exscientia and Insilico as Global Pharma Commits $500M+ to Collaborative Discovery?
Strategic Overview Standigm is emerging as a distinctive force in AI-driven drug discovery by grounding…
Gallery
